Mortality in CAD patients compared with individuals in general population matched comparison cohort
| Outcome . | Overall analysis for patients with CAD (n = 72) and matched controls (n = 720) . | Sensitivity analysis for patients with primary CAD (n = 59) and matched controls (n = 585) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CAD cohort patient deaths, n (%) . | Control cohort patient deaths, n (%) . | Crude HR (95% CI) . | aHR* (95% CI) . | P . | CAD cohort patient deaths, n (%) . | Control cohort patient deaths, n (%) . | Crude HR (95% CI) . | aHR* (95% CI) . | P . | |
| Mortality (entire follow-up) | 22 (30.6) | 114 (15.8) | 2.69 (1.66-4.35) | 1.84 (1.10-3.06) | .020 | 18 (30.5) | 93 (15.8) | 3.02 (1.76-5.17) | 2.35 (1.34-4.13) | .003 |
| First 5 y after diagnosis/study entry | 20 (27.8) | 82 (11.4) | 3.20 (1.92-5.33) | 2.27 (1.32-3.89) | .003 | 16 (27.1) | 65 (11.0) | 3.55 (1.99-6.33) | 3.00 (1.64-5.48) | .0004 |
| Outcome . | Overall analysis for patients with CAD (n = 72) and matched controls (n = 720) . | Sensitivity analysis for patients with primary CAD (n = 59) and matched controls (n = 585) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CAD cohort patient deaths, n (%) . | Control cohort patient deaths, n (%) . | Crude HR (95% CI) . | aHR* (95% CI) . | P . | CAD cohort patient deaths, n (%) . | Control cohort patient deaths, n (%) . | Crude HR (95% CI) . | aHR* (95% CI) . | P . | |
| Mortality (entire follow-up) | 22 (30.6) | 114 (15.8) | 2.69 (1.66-4.35) | 1.84 (1.10-3.06) | .020 | 18 (30.5) | 93 (15.8) | 3.02 (1.76-5.17) | 2.35 (1.34-4.13) | .003 |
| First 5 y after diagnosis/study entry | 20 (27.8) | 82 (11.4) | 3.20 (1.92-5.33) | 2.27 (1.32-3.89) | .003 | 16 (27.1) | 65 (11.0) | 3.55 (1.99-6.33) | 3.00 (1.64-5.48) | .0004 |
Match variables included year of birth, sex, and region of residence. Model also included adjustment for CCI score.